Home › Funds › Privium Fund Management B.V. › ARWR

Privium Fund Management B.V. position in ARWR

ARROWHEAD PHARMACEUTICALS IN · Health Care

Privium Fund Management B.V. reported holding 215,818 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$14.1M, representing 2.74% of its reported portfolio and ranking #12 among its reported holdings. Privium Fund Management B.V. has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)215.82K sh
Reported value held$14.13M
Portfolio Weight2.74%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Privium Fund Management B.V.'s ARWR position evolved

Privium Fund Management B.V. first disclosed a stake in ARWR in Q3 2023 at 259,036 shares (US$7.0M). The position peaked in Q4 2025 at 398,204 shares, worth US$26.4M. Across 13 filings, Privium Fund Management B.V. increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 215,818 shares valued at US$14.1M — a reduction of -18,404 shares quarter over quarter.. Notable position changes include a 65% increase in Q1 2025 (shares rose 24% over the following quarter), a 36% trim in Q2 2026 (shares fell 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 259.04K $6.96M New
Q4 2023 273.94K $8.49M Add
Q1 2024 273.94K $7.83M Hold
Q2 2024 286.94K $7.24M Add
Q3 2024 333.36K $6.46M Add
Q4 2024 380.59K $7.16M Add
Q1 2025 629.21K $8.02M Add
Q2 2025 612.21K $9.85M Reduce
Q3 2025 473.95K $16.35M Reduce
Q4 2025 398.20K $26.44M Reduce
Q1 2026 366.94K $23.01M Reduce
Q2 2026 234.22K $19.09M Reduce
Q3 2026 215.82K $14.13M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 43 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has Privium Fund Management B.V. held ARWR?

Privium Fund Management B.V. has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Privium Fund Management B.V.'s current position in ARWR?

As of Q3 2026, Privium Fund Management B.V. holds 215.82K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $14.13M, representing 2.74% of its reported portfolio and ranking #12.

Has Privium Fund Management B.V. been buying or selling ARWR?

In the latest 13F filing (Q3 2026), Privium Fund Management B.V. reduced its position in ARWR. The position peaked in Q4 2025 at 398.20K shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.